TargetMol

AM-36

Product Code:
 
TAR-T29939
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T29939-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T29939-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T29939-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
AM-36 is a potent Na+ channel blocker and antioxidant.
CAS:
199467-52-2
Formula:
C27H39ClN2O2
Molecular Weight:
459.07
Purity:
0.98
SMILES:
CC(C)(C)c1cc(CN2CCN(CC(O)c3ccc(Cl)cc3)CC2)cc(c1O)C(C)(C)C

References

1. Nicolazzo JA, Nguyen TT, Katneni K, Steuten JA, Smith G, Jarrott B, Callaway JK, Charman SA. Pharmacokinetics and brain uptake of AM-36, a novel neuroprotective agent, following intravenous administration to rats. J Pharm Pharmacol. 2008 Feb;60(2):171-8. doi: 10.1211/jpp.60.2.0005. PubMed PMID: 18237464. 2. Weston RM, Jarrott B, Ishizuka Y, Callaway JK. AM-36 modulates the neutrophil inflammatory response and reduces breakdown of the blood brain barrier after endothelin-1 induced focal brain ischaemia. Br J Pharmacol. 2006 Nov;149(6):712-23. Epub 2006 Oct 3. PubMed PMID: 17016500; PubMed Central PMCID: PMC2014659. 3. Callaway JK, Castillo-Melendez M, Giardina SF, Krstew EK, Beart PM, Jarrott B. Sodium channel blocking activity of AM-36 and sipatrigine (BW619C89): in vitro and in vivo evidence. Neuropharmacology. 2004 Jul;47(1):146-55. PubMed PMID: 15165842. 4. Callaway JK, Lawrence AJ, Jarrott B. AM-36, a novel neuroprotective agent, profoundly reduces reactive oxygen species formation and dopamine release in the striatum of conscious rats after endothelin-1-induced middle cerebral artery occlusion. Neuropharmacology. 2003 May;44(6):787-800. PubMed PMID: 12681377.